Partner Research Centers:

Center for Neurodegenerative Disease Research

Drug Discovery

Through the Marian S. Ware Alzheimer and Benaroya Parkinson's Disease Drug Discovery programs, Penn's CNDR has created a unique drug development program, which harnesses the team's biological understanding of neurodegenerative diseases and bridges the "valley of death" from lab research to pharmaceutical development.

The team investigates various drug targets and collaborates with industry partners on translational research projects.

Latest Research

Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.

PLoS One. 2015 May 1; Authors: Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, DeCarr L, Keenan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, Barrezueta N, Polson C, Wes P, Rangan VS, Cacace A, Albright CF, Meredith J, Trojanowski JQ, Lee VM, Brunden KR, Ahlijanian M

Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine.

Bioorg Med Chem Lett. 2015 Mar 14; Authors: Cornec AS, James MJ, Kovalevich J, Trojanowski JQ, Lee VM, Smith AB, Ballatore C, Brunden KR

Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice.

Neurobiol Dis. 2015 Jan; Authors: Peeraer E, Bottelbergs A, Van Kolen K, Stancu IC, Vasconcelos B, Mahieu M, Duytschaever H, Ver Donck L, Torremans A, Sluydts E, Van Acker N, Kemp JA, Mercken M, Brunden KR, Trojanowski JQ, Dewachter I, Lee VM, Moechars D

Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

Bioorg Med Chem. 2014 Sep 15; Authors: Brunden KR, Trojanowski JQ, Smith AB, Lee VM, Ballatore C

Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group.

Bioorg Med Chem Lett. 2014 Sep 1; Authors: Ballatore C, Gay B, Huang L, Robinson KH, James MJ, Trojanowski JQ, Lee VM, Brunden KR, Smith AB

Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists.

ACS Med Chem Lett. 2014 Sep 11; Authors: Wang X, Liu L, Huang L, Herbst-Robinson K, Cornec AS, James MJ, Sugiyama S, Bassetto M, Brancale A, Trojanowski JQ, Lee VM, Smith AB, Brunden KR, Ballatore C

Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.

Expert Opin Ther Pat. 2014 Mar; Authors: Ballatore C, Smith AB, Lee VM, Trojanowski JQ, Brunden KR

MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.

ACS Med Chem Lett. 2013 Sep 12, eCollection 2013 July; Authors: Brunden KR, Gardner NM, James MJ, Yao Y, Trojanowski JQ, Lee VM, Paterson I, Ballatore C, Smith AB

Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy.

J Biol Chem. 2013 May 24; Authors: Tanik SA, Schultheiss CE, Volpicelli-Daley LA, Brunden KR, Lee VM

Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease.

ACS Chem Neurosci. 2012 Nov 21; Authors: Soper JH, Sugiyama S, Herbst-Robinson K, James MJ, Wang X, Trojanowski JQ, Smith AB, Lee VM, Ballatore C, Brunden KR